cetuximab

You have access
Effectiveness of Hyperthermia as Monotherapy and Adjuvant Therapy Approaches Against an In Vitro Model of Colorectal Carcinoma
GEORGIOS PETRAKIS, THEODORA MANTSO, MICHAIL I. KOUKOURAKIS, MIHALIS I. PANAYIOTIDIS and SOTIRIS BOTAITIS

Anticancer Research May 2022, 42 (5) 2363-2374; DOI: https://doi.org/10.21873/anticanres.15715
You have access
Phase II Study of S-1 and Irinotecan Plus Bevacizumab as Second-line Treatment for Patients With Metastatic Colorectal Cancer Resistant to the Fluoropyrimidine-oxaliplatin-cetuximab Regimen
HIROAKI TANIOKA, KEN SHIMADA, AKIHITO TSUJI, MITSUGU KOCHI, HO MIN KIM, TAKAO TAKAHASHI, TADAMICHI DENDA, AKINORI TAKAGANE, TAKANORI WATANABE, MASAHITO KOTAKA, MASATO NAKAMURA, YU SUNAKAWA, MASAHIRO TAKEUCHI, WATARU ICHIKAWA and MASASHI FUJII

Anticancer Research May 2022, 42 (5) 2675-2681; DOI: https://doi.org/10.21873/anticanres.15745
You have access
Multicenter Retrospective Study of Weekly Cetuximab Plus Paclitaxel for Recurrent or Metastatic Oral Squamous Cell Carcinoma
TOMOFUMI NARUSE, SOUICHI YANAMOTO, MITSUNOBU OTSURU, NOBUHIRO YAMAKAWA, TADAAKI KIRITA, YUKARI SHINTANI, TATSUSHI MATSUMURA, MASAYA OKURA, MASASHI SASAKI, YOSHIHIDE OTA, SHIN-ICHI YAMADA, HIROSHI KURITA, MASAHIRO UMEDA and JAPAN ORAL ONCOLOGY GROUP (JOOG)

Anticancer Research November 2021, 41 (11) 5785-5791; DOI: https://doi.org/10.21873/anticanres.15395
You have access
PTEN Is Activated by the Addition of Cetuximab to Paclitaxel in Oral Squamous Cell Carcinoma
TOMOYUKI KII, KANAME SAKUMA and AKIRA TANAKA

Anticancer Research July 2021, 41 (7) 3363-3370; DOI: https://doi.org/10.21873/anticanres.15124
Open Access
Modified TPEx as First-line Treatment for Recurrent and/or Metastatic Head and Neck Cancer
MOTOYUKI SUZUKI, YUKINORI TAKENAKA, TOSHIHIRO KISHIKAWA, YOSHIFUMI YAMAMOTO, ATSUSHI HANAMOTO, YOICHIRO TOMIYAMA, TAKAHITO FUKUSUMI, TAKAHIRO MICHIBA, NORIHIKO TAKEMOTO, SUSUMU NAKAHARA and HIDENORI INOHARA

Anticancer Research April 2021, 41 (4) 2045-2051; DOI: https://doi.org/10.21873/anticanres.14973
You have access
Effects of Type of Antibody to EGFR and Hypomagnesemia on Overall Survival in First-line Treatment of Patients With Unresectable Advanced/Recurrent Colorectal Cancer
MICHIO KIMURA, EISEKI USAMI and TOMOAKI YOSHIMURA

Anticancer Research December 2020, 40 (12) 7135-7140; DOI: https://doi.org/10.21873/anticanres.14743
You have access
Comparison Between Biweekly and Weekly Cetuximab in Patients With Metastatic Colorectal Cancer: A Meta-analysis
AKIHISA MATSUDA, TAKESHI YAMADA, SUPASCHIN JAMJITTRONG, SEIICHI SHINJI, RYO OHTA, HIROMICHI SONODA, TUNYAPORN KAMONVARAPITAK, KUMIKO SEKIGUCHI, MASAO MIYASHITA, HIDEYUKI SUZUKI and HIROSHI YOSHIDA

Anticancer Research June 2020, 40 (6) 3469-3476; DOI: https://doi.org/10.21873/anticanres.14333
You have access
The Predictive Role of Primary Tumour Sidedness in Metastatic Colorectal Cancer Treated With Targeted Agents
ONDREJ FIALA, PAVEL OSTASOV, PETR HOSEK, ONDREJ SOREJS, VACLAV LISKA, TOMAS BUCHLER, ALEXANDR POPRACH, RADEK KUCERA, ONDREJ TOPOLCAN, JAN SUSTR, MONIKA SEDIVCOVA and JINDRICH FINEK

Anticancer Research October 2019, 39 (10) 5645-5652; DOI: https://doi.org/10.21873/anticanres.13761
You have access
Relationship Between EGFR Expression in Oral Cancer Cell Lines and Cetuximab Antibody-dependent Cell-mediated Cytotoxicity
HIROSHI NAKAMURA, SHIGEHIRO TAMAKI, TAKAHIRO YAGYUU, NOBUHIRO YAMAKAWA, KATSUHIKO HATAKE and TADAAKI KIRITA

Anticancer Research March 2019, 39 (3) 1275-1282; DOI: https://doi.org/10.21873/anticanres.13238
You have access
Radiolabeling, Characteristics and NanoSPECT/CT Imaging of 188Re-cetuximab in NCI-H292 Human Lung Cancer Xenografts
WAN-I KUO, KAI-HUNG CHENG, YA-JEN CHANG, TSUNG-TSE WU, WEI-CHUAN HSU, LIANG-CHENG CHEN and CHIH-HSIEN CHANG

Anticancer Research January 2019, 39 (1) 183-190; DOI: https://doi.org/10.21873/anticanres.13096

Main menu

User menu

Search

cetuximab

Pages